Leonard Mazur

Recent appearances

• 

  Citius’ Leonard Mazur talks targeted immune therapy for CTCL

  June 23, 2026 · 📺 pharmaphorum media limited

  Cutaneous T-cell lymphoma (or CTCL) is a rare form of non-Hodgkin lymphoma that begins in T lymphocytes, a kind of white blood cell that plays a crucial role in the immune system. And Citius Oncology is focused on developing and commercialising a targeted immune therapy for the initial indication of the treatment of persistent or recurrent CTCL. In a new pharmaphorum podcast, web editor Nicole Raleigh spoke with Leonard Mazur, CEO and Chairman of Citius Pharmaceuticals about the launch of its first FDA-approved drug, Lymphir, for CTCL. Mazur discusses the landscape of unmet need in this…

  Watch on YouTube ↗

• 

  Episode 187 - Leonard Mazur - CEO Citius Pharma

  June 10, 2026 · 📺 The Biohub

  In this episode of The BioHub Podcast, Max sits down with Leonard Mazur, Chairman and CEO of Citius Pharmaceuticals. Leonard is a seasoned entrepreneur and pharmaceutical executive who has spent decades building, scaling, and commercializing healthcare companies. Throughout his career, he has founded multiple successful businesses, led major transactions, and helped bring innovative therapies to patients across a range of therapeutic areas. In this conversation, we discuss Leonard's journey as a serial entrepreneur, the lessons he's learned from building companies from the ground up, and t…

  Watch on YouTube ↗

• 

  DBC Webinar - Citius Pharmaceuticals: From Development Stage to Commercial Oncology

  March 12, 2026 · 📺 D. Boral Capital

  Citius Pharmaceuticals has officially crossed a major threshold. After years as a development-stage biotech, the company has reported its first commercial revenue, following the U.S. launch of LYMPHIR, generating $3.9M in fiscal Q1 sales, in what can be viewed as a strategic inflection point. Now the key question becomes: How does Citius scale from its initial oncology launch to deliver meaningful revenue visibility in 2026, and beyond? Review this live webinar recording with Jason Kolbert, Head of Research at D. Boral Capital and Leonard Mazur, Chairman and Chief Executive Officer of Citius…

  Watch on YouTube ↗

• 

  Leonard Mazur CEO Of Citius Pharmasuticals

  August 25, 2025 · 📺 Danaya Azure

  Leonard Mazur CEO Of Citius Pharmasuticals www.danayaazure.com https://citiuspharma.com/ Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is a late-stage biopharmaceutical company focused on the development and commercialization of first-in-class critical care products, with a pipeline of anti-infectives in adjunct cancer care, oncology, stem cell therapy and unique prescription products. LYMPHIR™ (denileukin diftitox-cxdl), our targeted immune therapy for adult patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL) is now approved by the FDA. Commercialization efforts are und…

  Watch on YouTube ↗

• 

  Success Lessons from a Serial Entrepreneur with Leonard Mazur

  May 14, 2025 · 📺 Biotech CEO Stories

  Enjoy this podcast with Leonard Mazur, the co-founder, Chairman, and CEO of Citius Pharmaceuticals, a late-stage biopharma company focused on developing critical care. With over 50 years in the industry, there are many success lessons to be learned as Leonard has co-founded several companies, including Akrimax Pharmaceuticals and Genesis Pharmaceuticals, which he successfully sold to Pierre Fabre in 2003. Disclaimer The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights i…

  Watch on YouTube ↗

• 

  Innovating Biopharma & Pioneering Critical Care Solutions - Leonard Mazur

  April 17, 2024 · 📺 Life Science Success

  In this episode of the Life Science Success Podcast our guest is Leonard Mazur, CEO and Co-Founder of Citius Pharmaceuticals. With over 50 years of experience in the biopharma industry, Leonard has been at the forefront of developing groundbreaking therapies for patients with unmet medical needs.

  Watch on YouTube ↗

• 

  Diversified Pipeline of Critical Care Products 多元化的重症監護產品 | Citius Pharmaceuticals (NASDAQ: CTXR)

  December 08, 2023 · 📺 NAI500andGCFF

  We are honored to invite Leonard Mazur, Co-Founder, CEO, and Chairman of the Board of #citius #Pharmaceuticals , to this interview again to introduce the company's overview and the progress of related major pharmaceutical products. Leonard emphasized that Citius has a diversified pipeline including two late-stage product candidates: LYMPHIR™ and Mino-Lok®. Also, Citius has $33.3 M cash as of 6/30/2023 with runway through August 2024. 我們很榮幸再次邀請到Citius Pharmaceuticals聯合創始人、首席執行官兼董事會主席Leonard Mazur接受本次采訪，介紹公司概況以及相關主要醫藥產品的進展。 Leonard 強調，Citius 擁有多元化的產品線，包括兩種後期候選產品：LYMPHIR™ 和 Mino-Lok®。 此外，截至 2023…

  Watch on YouTube ↗

• 

  Advancing Diversified Pipeline with Multiple Active Programs | Citius Pharmaceuticals (NASDAQ: CTXR)

  December 02, 2023 · 📺 NAI500andGCFF

  #Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) is a late-stage #biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapies. The Company’s diversified pipeline includes two late-stage product candidates. Mino-Lok®, an antibiotic lock solution for the treatment of patients with catheter-related bloodstream infections, is enrolling patients in a Phase 3 Pivotal superiority trial and was granted Fast Track designation by t…

  Watch on YouTube ↗

• 

  Veteran Advice From The C-Suite With Citius' Leonard Mazur

  October 09, 2023 · 📺 Life Science Connect

  Leonard Mazur has been in the business of biotech for a long, long time, and having tasted the thrill of victory despite the agony of defeat biopharma so commonly doles, he has no intention of stopping now. He’s faced challenges won, lost, and ongoing, and he’s willing to share a host of his experiences—from winning FDA approvals to bootstrapping his current effort at Citius Pharmaceuticals to overcoming a CRL and more—with the transparent confidence of an industry veteran. Don’t miss the solid dose of life sciences business wisdom on display on this episode of the Business of Biotech. --- #…

  Watch on YouTube ↗

• 

  Invest In Relationships with Leonard Mazur | Management Blueprint Podcast

  May 29, 2023 · 📺 Steve Preda

  Join Leonard Mazur, CEO of Citius Pharma, on Management Blueprint Podcast to learn about investing in relationships. Discover the benefits of nurturing professional connections and explore biopharma investment opportunities. Get insights on minimizing investment risks. Time Stamps [00:42] Leonard’s entrepreneurial journey [04:13] Leonard’s experience with management blueprints [09:10] Investing in extremely unique opportunities [10:30] Why believing in your product is essential for success [12:42] Why you need to invest in your relationships [16:15] Investing in a Biotech company [19:02] How…

  Watch on YouTube ↗

• 

  Manor College Founder's Day 2022 | Leonard Mazur Keynote Address

  January 27, 2022 · 📺 Manor College

  Leonard Mazur, the Executive Chairman and Director of Citius Pharmaceuticals and a Manor College Board of Trustees member, delivers the keynote address for the institution's annual Founders' Day on Jan. 27, 2022.

  Watch on YouTube ↗

• 

  Citius Pharmaceuticals (CTXR) Executive Chairman Leonard Mazur – Presentation from NobleCon17

  February 12, 2021 · 📺 channelchek

  Citius Pharmaceuticals Executive Chairman Leonard Mazur’s presentation from NobleCon17, January 2021. Following a formal presentation, Leonard is joined by Noble Capital Markets Senior Research Analyst Ahu Demir, PhD for a Q&A session, featuring questions submitted by the NobleCon live audience. More information on Citius Pharmaceuticals, including recent news and advanced market data is available (at no cost) at https://www.channelchek.com/company/CTXR Citius Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in the development and commercialization of antiin…

  Watch on YouTube ↗